Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.55 USD | -5.62% |
|
-13.82% | -25.14% |
Jun. 05 | Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating | MT |
Jun. 04 | FDA panel to review psychedelic drug MDMA for first time | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.14% | 475M | |
+49.41% | 57.87B | |
+41.65% | 40.25B | |
-6.72% | 39.94B | |
-5.96% | 28.54B | |
+12.99% | 26.4B | |
-19.82% | 19.33B | |
+32.35% | 12.4B | |
-0.08% | 12.23B | |
+25.18% | 12.2B |
- Stock Market
- Equities
- CMPS Stock
- News COMPASS Pathways plc
- Compass Pathways Insider Sold Shares Worth $902,124, According to a Recent SEC Filing